Guardant Health
Guardant Health’s Q1 Revenue Soars 48% to $301.7M, Driven by Impressive Screening Expansion
Guardant Health Inc. (NASDAQ: GH) is making waves in the oncology sector. Recently, the company reported impressive first-quarter revenue of ... Read more
Exciting Data Reveal: Guardant Health (NASDAQ: GH) Shows 43.9% of 20,000 Patients Prefer Blood Tests!
Guardant Health is changing the way we think about cancer screening. They’ve announced new findings about their blood-based test, Shield, ... Read more
